Interestingly, examination by four hot-tumor gene signatures showed that tumors with a high abundance of TCL1A+ B cells showed hot-tumor characterization, indicating that an immune checkpoint inhibitors-based therapy strategy might be helpful in such patients [42]. The gene discussed is TCL1A; the disease is neoplasm.